Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.

The Journal of biological chemistry - 29 Nov 2019

Sato Yukiko, Thomas David Y, Hanrahan John W

Abstract excerpt

Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) disrupt epithelial secretion and cause cystic fibrosis (CF). Available CFTR modulators provide only modest clinical benefits, so alternative therapeutic targets are being explored. The anion-conducting transporter solute carrier family 26 member 9 (SLC26A9) is a promising candidate, but its functional expression is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiporters
Share to Bronchi
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoplasmic Reticulum

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Sulfate Transporters

Share to Tight Junctions

Source

Open in PubMed Open full text

Identifiers

PMID: 31645438
DOI: 10.1074/jbc.RA119.010192
PMCID: PMC6885613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.PMID 31645438Read ↗

The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.Semantic proximity Read ↗

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.Semantic proximity Read ↗

A novel SLC26A9 inhibitor, S9-A13, reveals a minor contribution of SLC26A9 to constitutive airway chloride secretionSemantic proximity Read ↗

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.Semantic proximity Read ↗

SLC26A9 stimulates CFTR expression and function in human bronchial cell linesSemantic proximity Read ↗

Structure, function, and trafficking of SLC4 and SLC26 anion transporters.Semantic proximity Read ↗

Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosisSemantic proximity Read ↗

Functional comparison of mouse slc26a6 anion exchanger with human SLC26A6 polypeptide variants: differences in anion selectivity, regulation, and electrogenicity.Semantic proximity Read ↗

The multiple ubiquitination mechanisms in CFTR peripheral quality control.Semantic proximity Read ↗

Degradation of CFTR-F508del By the Ubiquitin E2 Conjugating Enzyme UBE 2L6 and the E3 Ligase RNF19BSemantic proximity Read ↗

Inhibition of the QPCT-PDIA4 axis rescues ΔF508 and N1303K CFTR in cystic fibrosis.Semantic proximity Read ↗

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.